Intelligence Feed event · Policy · 2026-09-24

    Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial

    Question

    Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial

    Direct answer

    Vertex Pharmaceuticals released Phase IIb AMPLIFIED study data evaluating inaxaplin in APOL1-mediated kidney disease (AMKD). The oral small-molecule inhibitor achieved a 42.7% reduction in urinary albumin-to-creatinine ratio (UACR) in AMKD patients presenting with modest proteinuria, and a 17.3% reduction in patients with concurrent type II diabetes. The company confirmed that patient enrollment in the pivotal Phase II/III AMPLITUDE trial is now complete, providing a defined timeline for registrational efficacy endpoints.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-24
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial”, revision 1, evidence through 2026-09-24. https://marketontology.com/market-events/2026-09-24/vertex-inaxaplin-phase-iib-cuts-proteinuria-in-kidney-disease-trial-07180c

    POLICY
    Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial
    Vertex Pharmaceuticals released Phase IIb AMPLIFIED study data evaluating inaxaplin in APOL1-mediated kidney disease (AMKD). The oral small-molecule inhibitor achieved a 42.7% reduction in urinary albumin-to-creatinine ratio (UACR) in AMKD patients presenting with modest proteinuria, and a 17.3% reduction in patients with concurrent type II diabetes. The company confirmed that patient enrollment in the pivotal Phase II/III AMPLITUDE trial is now complete, providing a defined timeline for registrational efficacy endpoints.
    VRTX
    Impact
    70
    SEP 24
    SIG
    85%
    VRTX
    Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial
    Vertex Pharmaceuticals released Phase IIb AMPLIFIED study data evaluating inaxaplin in APOL1-mediated kidney disease (AMKD). The oral small-molecule inhibitor achieved a 42.7% reduction in urinary albumin-to-creatinine ratio (UACR) in AMKD patients presenting with modest proteinuria, and a 17.3% reduction in patients with concurrent type II diabetes. The company confirmed that patient enrollment in the pivotal Phase II/III AMPLITUDE trial is now complete, providing a defined timeline for registrational efficacy endpoints.
    → Statistically significant UACR reductions derisk inaxaplin pivotal Phase III AMPLITUDE outcomes, improving VRTX medium-term non-cystic fibrosis franchise valuations.
    Impact
    Vertex Pharmaceuticals released Phase IIb AMPLIFIED study data evaluating inaxaplin in APOL1-mediated kidney disease (AMKD). The oral small-molecule inhibitor achieved a 42.7% reduction in urinary albumin-to-creatinine ratio (UACR) in AMKD patients presenting with modest proteinuria, and a 17.3% reduction in patients with concurrent type II diabetes. The company confirmed that patient enrollment in the pivotal Phase II/III AMPLITUDE trial is now complete, providing a defined timeline for registrational efficacy endpoints.
    Affected
    VRTX
    Transmission
    Statistically significant UACR reductions derisk inaxaplin pivotal Phase III AMPLITUDE outcomes, improving VRTX medium-term non-cystic fibrosis franchise valuations.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    VRTXclinical pipeline expansion into nephrology beyond core cystic fibrosis portfolioUp1-5dVertex posted Phase IIb AMPLIFIED study showing 42.7% UACR reduction and completed AMPLITUDE pivotal study enrollment.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed522.38 2026-09-24+0.73%-2.99%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month